- Welcome to the New Journal Cardiovascular Prevention and Pharmacotherapy
-
Mi-Jeong Kim, Jang-Whan Bae, Dae Ryong Kang
-
Cardiovasc Prev Pharmacother. 2019;1(1):1-2. Published online July 31, 2019
-
DOI: https://doi.org/10.36011/cpp.2019.1.e5
-
-
 PDF
- Role of Novel Oral Anticoagulant for Patient with Atrial Fibrillation Underwent Percutaneous Coronary Intervention
-
Jang-Whan Bae
-
Cardiovasc Prev Pharmacother. 2019;1(1):19-29. Published online July 31, 2019
-
DOI: https://doi.org/10.36011/cpp.2019.1.e1
-
-
2,157
View
-
17
Download
-
1
Citations
-
 Abstract
PDF
- Atrial fibrillation (AF) is very common arrhythmic disorder especially in elderly population, and makes higher major adverse cardiac events (MACEs) in the patients with acute coronary syndrome (ACS) or underwent percutaneous coronary intervention (PCI). Pivotal drug for AF patients to reduce systemic embolism was warfarin, and certain duration of dual antiplatelet therapy (DAPT) is important after PCI with stent. But, best regimen of antithrombotic agent after PCI in AF is unclear especially in the clinical use of novel oral anticoagulant (NOAC). This manuscript will deal those clinical studies to indicate optimal regimen and duration of NOAC use for AF patients underwent PCI. NOAC use on DAPT significantly reduces major or minor bleeding compared to warfarin in AF patients with ACS or underwent PCI. But, the duration of NOAC use is still unclear, and there is exist clear contraindication to use it in clinical field. NOAC use reduced major or minor bleeding significantly compared to warfarin, but the incidence of MACEs was similar between warfarin and NOAC. Physician should understand the advantage or disadvantage of NOAC use, and be able to tailor the regimen and duration of antithrombotics including NOAC in this higher risk patient population.
-
Citations
Citations to this article as recorded by  - Welcome to the New JournalCardiovascular Prevention and Pharmacotherapy
Mi-Jeong Kim, Jang-Whan Bae, Dae Ryong Kang
Cardiovascular Prevention and Pharmacotherapy.2019; 1(1): 1. CrossRef
|
